Here's some of what is coming soon to NeurologyLive® this week.
|Videos|June 17, 2021
Multiple Sclerosis Care During a Pandemic
Join Ahmed Obeidat, MD, PhD; Anne Cross, MD; and Gloria von Geldern, MD, for the third program in this series, where they offer insight from neurology specialists on applying lessons learned from the COVID-19 pandemic into clinical practice when managing patients with multiple sclerosis.
Advertisement
————————————
Panelists
- Ahmed Obeidat, MD, PhD
Assistant Professor, Department of Neurology, Neuroimmunology and Multiple Sclerosis; Director, Neuroimmunology and MS Fellowship Program, The Medical College of Wisconsin - Anne Cross, MD
Professor of Neurology; Section Head, Neuroimmunology/Multiple Sclerosis, Washington University School of Medicine - Gloria von Geldern, MD
Associate Professor of Neurology, University of Washington
Key Learning Objectives
- Adapting to virtual MS visits during COVID-19 including pros and cons
- Continuation of MS multidisciplinary care during COVID-19
- Impact of COVID-19 on MS research
- COVID-19 vaccine considerations in patients with MS
Advertisement
Related to this article
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 18, 2026.
Brian Lin, PhD, discussed the current evidence linking football participation with ALS, the questions that remain unanswered, and how emerging research may help clarify the association.
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jennifer Fokas, MD, and Minali Nigam, MD. [LISTEN TIME: 21 minutes]
A recent MS cohort study suggests that higher EBV nuclear antigen 1 antibody levels are associated with a lower risk of confirmed disability worsening, particularly among patients carrying both HLA-A02:01 and HLA-DRB115:01.
The FDA clearance allows AbelZeta to study bispecific CAR T-cell therapy C-CAR168 in refractory progressive multiple sclerosis.
Robert Bowser, PhD, chief scientific officer at Barrow Neurological Institute, recaps his ALS Nexus presentation on TDP-43 biology, the emerging therapeutic landscape, and how cryptic peptide biomarkers could reshape ALS clinical trial design.
KuangHua Guo, MD, PhD, sleep specialist at Northwestern Medicine, discussed emerging orexin agonist therapies and refined diagnostic approaches for hypersomnia.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Levacetylleucine for Ataxia-Telangiectasia
2
Gefurulimab Recommended for EU Approval in Generalized Myasthenia Gravis
3
Episode 175: Advancing the Ways of Treating Cluster Headache
4
FDA Approves UX111, First Gene Therapy for Pediatric Sanfilippo Syndrome Type A
5